Consun Pharmaceutical Group Ltd.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. carries a market capitalization of 1.38B, placing it among publicly traded companies globally. Its enterprise value stands at 965.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Consun Pharmaceutical Group Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. has 839.96M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. maintains a current ratio of 3.22, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 7, 2026, Consun Pharmaceutical Group Ltd.'s stock has declined approximately 4.64% over the past 52 weeks. The 50-day moving average sits at 1.47, while the 200-day moving average is 1.64.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. holds 475.11M in cash and equivalents against 25.92M in total debt, resulting in a net debt position of -125.90M. Total book value stands at 551.98M, with working capital of 386.38M providing operational flexibility.